StreetAlpha.app
Home › Stocks › DMAC

DiaMedica Therapeutics Inc. (DMAC)

$8.38
▲ +0.60%
LAST CLOSE · NOV 17

DiaMedica Therapeutics develops DM199, an experimental protein therapy for preeclampsia, fetal growth restriction and acute ischemic stroke. It last closed at $8.38 on Nov 17, up 0.60% on the day. DMAC last reported earnings on Thu, Nov 12, 2026.

AI Auto Pilots
Is DMAC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$40.2M
EPS (diluted)
−$0.75
Free cash flow
−$33.8M
Valuation
Market cap
$452.2M
54.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$6.8M
At Sep 30
Shareholder equity
$28.7M
Shares outstanding
54.0M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$13.6M−$13.6MFY2021FY2022: −$13.7M−$13.7MFY2022FY2023: −$19.4M−$19.4MFY2023FY2024: −$24.4M−$24.4MFY2024FY2025: −$32.8M−$32.8MFY2025

From DMAC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · After the close (AMC)
Reported EPS
-$0.21
vs -$0.20 est. · miss
Year-ago EPS
-$0.17
Same quarter last year
Options-implied move
±10.9%
Priced in before that report
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated DMAC in the past 90 days.
Average 12-month target
No price targets on DMAC in the past 90 days.
Latest rating changes
HC Wainwright & Co.Reiterated
Aug 11Buy$12
DateFirmActionRatingPrice target
Aug 11HC Wainwright & Co.ReiteratedBuy$12
Loading…

Technical Analysis

DMAC · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 14% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 45). The nearest support is the Pivot at $8.31, and the nearest resistance the swing high (Jul 6) at $8.53.

Short trendNeutral
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 8.3%/day
Key levels
$10.9852 week high+31.0%
$9.2220 day average+10.0%
$8.71Pivot R1+3.9%
$8.53Swing high (Jul 6)+1.8%
$8.38Last close
$8.31Pivot−0.8%
$8.2750 day average−1.3%
$7.99Pivot S1−4.7%
$7.66Swing low (Oct 8)−8.6%
$7.59100 day average−9.4%
$7.18200 day average−14.3%
$5.2552 week low−37.4%
Indicators
RSI (14)44.53Middle of its rangeNeutral
MACD0.16Below its signal lineBearish
Stochastic13.3Near the bottom of its rangeOversold
ADX (14)25.0Trending down
Williams %R-84.8Oversold below −80, overbought above −20Oversold
CCI (20)-128.2Oversold below −100, overbought above 100Oversold
Rate of change−16.2%Change over 10 sessionsBearish
ATR (14)$0.69Typical daily range, 8.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for DMAC

What happened before

See how DMAC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow DMAC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DMAC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in DMAC in the last 90 days.

Loading…

See today’s whale options flow across the market →

DMAC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲53 buying vs 26 selling
  • ●Held by funds +0.5 pts
  • ▲Funds holding +7
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9790+7.8%
In funds' top 1000–
Held by funds23.8%23.3%+0.5 pts
New / increased15 / 3811 / 32+23.3%
Reduced / sold out19 / 720 / 18−31.6%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DMAC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DMAC is in one of them and how their past DMAC trades turned out.

DMAC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DMAC in an article yet. Here's the latest on the wider market.

About DiaMedica Therapeutics

DiaMedica Therapeutics is a biopharmaceutical company based in Minneapolis, Minnesota. It is developing DM199, a recombinant form of the human tissue kallikrein-1 protein, as a possible treatment for preeclampsia, fetal growth restriction and acute ischemic stroke. The drug is still in clinical trials and is not yet approved for sale. The company is also working on DM300, a recombinant ulinastatin, as a possible treatment for severe acute pancreatitis.

Headquarters
Minneapolis, MN